Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627741 | 0.90 | GLA (0.54) | ALDH1A1GLAHTTL3MBTL1TSHR | |
| SCHEMBL17527131 | 0.77 | TSHR (0.49) | ALDH1A1L3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL8353377 | 0.77 | TSHR (0.53) | ALDH1A1L3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL17850623 | 0.75 | TSHR (0.55) | ALDH1A1L3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL4613472 | 0.74 | ALDH1A1 (0.58) | ALDH1A1GLAHTTL3MBTL1TSHR | |
| SCHEMBL23125676 | 0.72 | — | — | |
| SCHEMBL26355356 | 0.72 | — | — | |
| SCHEMBL1177432 | 0.72 | GLA (0.82) | ALDH1A1GLAL3MBTL1TSHRPOLB | |
| SCHEMBL14223107 | 0.72 | L3MBTL1 (0.51) | ALDH1A1GLAHTTL3MBTL1TSHR | |
| SCHEMBL14826081 | 0.72 | POLB (0.48) | ALDH1A1TSHRPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714036-B1 | SUBSITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | ACHILLION PHARMACEUTICALS INC (US) | 2016-06-22 | — | — | EP | disclosed |